A Study of Dasatinib in Patients With Chronic Myelogenous Leukemia Who Are Resistant or Intolerant of Imatinib Mesylate

PHASE2CompletedINTERVENTIONAL
Enrollment

400

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Leukemia, Myeloid, ChronicLeukemia, Lymphocytic, Acute, L2
Interventions
DRUG

Dasatinib

Tablets, Oral, 70 mg, Twice daily, 2 months.

Trial Locations (35)

Unknown

Local Institution, Corona

Local Institution, Aurora

Local Institution, Colorado Springs

Local Institution, Waterford

Local Institution, Daytona Beach

Local Institution, Jupiter

Local Institution, Atlanta

Local Institution, Lawrenceville

Local Institution, Beach Grove

Local Institution, Indianapolis

Local Institution, Iowa City

Local Institution, Kansas City

Local Institution, Salina

Local Institution, Lexington

Local Institution, Louisville

Local Institution, Boston

Local Institution, Ann Arbor

Local Institution, Detroit

Local Institution, Santa Fe

Local Institution, New York

Local Institution, Cincinnati

Local Institution, Cleveland

Local Institution, Lawton

Local Institution, Tulsa

Local Institution, Portland

Local Institution, Providence

Local Institution, Charleston

Local Institution, Chattanooga

Local Institution, Spokane

Local Institution, Sheboygan

Local Institution, Edmonton

Local Institution, Vancouver

Local Institution, Hamilton

Local Institution, Toronto

Local Institution, Montreal

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY